Compare · CODX vs VRAX

CODX vs VRAX

Side-by-side comparison of Co-Diagnostics Inc. (CODX) and Virax Biolabs Group Limited (VRAX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. CODX focuses on Medical/Dental Instruments, while VRAX focuses on Biotechnology: In Vitro & In Vivo Diagnostic Substances.
  • CODX is the larger of the two at $2.1M, about 3.6x VRAX ($602,555).
  • CODX has been more active in the news (13 items in the past 4 weeks vs 4 for VRAX).
  • CODX has more recent analyst coverage (3 ratings vs 1 for VRAX).
MetricCODXVRAX
Company
Co-Diagnostics Inc.
Virax Biolabs Group Limited
Price
-
-
Market cap
$2.1M
$602,555
1M return
-
-
1Y return
-
-
Industry
Medical/Dental Instruments
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Exchange
NASDAQ
NASDAQ
IPO
2026
2022
News (4w)
13
4
Recent ratings
3
1
CODX

Co-Diagnostics Inc.

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant and animal genomes. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

VRAX

Virax Biolabs Group Limited

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, and individual consumers. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. The company was incorporated in 2021 and is based in London, the United Kingdom.

Latest CODX

Latest VRAX